- Home
- DTST vs CURX Comparison
DTST vs CURX Comparison
Compare DTST & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- CURX
- Stock Information
- Founded
- DTST 2001
- CURX 2018
- Country
- DTST United States
- CURX United States
- Employees
- DTST N/A
- CURX N/A
- Industry
- DTST EDP Services
- CURX Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- CURX Health Care
- Exchange
- DTST Nasdaq
- CURX Nasdaq
- Market Cap
- DTST 32.6M
- CURX 29.7M
- IPO Year
- DTST N/A
- CURX 2025
- Fundamental
- Price
- DTST $4.18
- CURX $0.71
- Analyst Decision
- DTST Hold
- CURX
- Analyst Count
- DTST 1
- CURX 0
- Target Price
- DTST N/A
- CURX N/A
- AVG Volume (30 Days)
- DTST 59.3K
- CURX 2.7M
- Earning Date
- DTST 11-13-2025
- CURX 09-09-2025
- Dividend Yield
- DTST N/A
- CURX N/A
- EPS Growth
- DTST N/A
- CURX N/A
- EPS
- DTST N/A
- CURX N/A
- Revenue
- DTST $25,455,742.00
- CURX N/A
- Revenue This Year
- DTST N/A
- CURX N/A
- Revenue Next Year
- DTST N/A
- CURX N/A
- P/E Ratio
- DTST N/A
- CURX N/A
- Revenue Growth
- DTST 0.53
- CURX N/A
- 52 Week Low
- DTST $2.93
- CURX $3.61
- 52 Week High
- DTST $5.44
- CURX $8.60
- Technical
- Relative Strength Index (RSI)
- DTST 45.02
- CURX N/A
- Support Level
- DTST $4.12
- CURX N/A
- Resistance Level
- DTST $4.38
- CURX N/A
- Average True Range (ATR)
- DTST 0.18
- CURX 0.00
- MACD
- DTST 0.01
- CURX 0.00
- Stochastic Oscillator
- DTST 46.06
- CURX 0.00
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About CURX Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.